Alternatives to upadacitinib
2 same-class SPL records vs upadacitinib - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.
Brand: Rinvoq
How to read a high-report FAERS peer set
upadacitinib ranks in the upper FAERS-volume third of the corpus (#99 of 524); 2 same-class peers are listed for field comparison only. Labeled indication field for upadacitinib: Rinvoq can treat rheumatoid arthritis, psoriatic arthritis, atopic dermatitis (eczema), ulcerative colitis, Crohn’s disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis.
Top FAERS reaction fields for upadacitinib total 28,494 reports across 10 reactions, set beside baricitinib, tofacitinib. Counts are exposure-weighted submissions, not per-patient risk.
About upadacitinib
Rinvoq contains upadacitinib and it is a medicine that reduces inflammation in your body. It is used to treat several conditions, including arthritis and Crohn's disease.
Used for: Rinvoq can treat rheumatoid arthritis, psoriatic arthritis, atopic dermatitis (eczema), ulcerative colitis, Crohn’s disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis. It is used when other medicines, like TNF blockers, have not worked well enough. For ulcerative colitis and Crohn's disease, you should have tried at least one other approved medicine before using Rinvoq if TNF blockers are not suitable for you.
2 JAK Inhibitor peers (wide set)
baricitinib
RxOlumiant
Olumiant treats rheumatoid arthritis in adults when other medicines have not worked well. Rheumatoid arthritis is a disease that causes pain, swelling, and stiffness in the joints. Olumiant can also be used to treat alopecia areata, a condition that causes patchy hair loss.
tofacitinib
RxXeljanz
Xeljanz treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis in adults. It is also used to treat psoriatic arthritis and juvenile idiopathic arthritis in children 2 years and older. It is for people who have not responded well to TNF blockers. Do not use Xeljanz with other strong immunosuppressants.
upadacitinib vs baricitinib & tofacitinib · FAERS reaction fields
FAERS top-reaction field "Pain" shows the widest count spread between upadacitinib and baricitinib, tofacitinib in this extract (20,795-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | upadacitinib | baricitinib | tofacitinib |
|---|---|---|---|
| Pain | 4,942 | 173 | 25,737 |
| Arthralgia | 4,342 | 179 | 19,670 |
| Covid-19 | 3,131 | 439 | - |
| Rheumatoid Arthritis | 3,037 | 352 | 18,797 |
| Pain In Extremity | 2,575 | - | 10,277 |
| Fatigue | 2,433 | 183 | 16,595 |
| Fall | 2,255 | - | - |
| Surgery | 2,204 | - | - |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
upadacitinib FAERS volume vs class peers
FAERS volume band
upadacitinib is FAERS corpus rank #99 of 524 (high volume tercile). Top-reaction field total: 28,494.
Frequently Asked Questions
Where does upadacitinib sit in FAERS report volume vs JAK Inhibitor peers? ▼
Registry note: FAERS counts are voluntary reports and do not establish causation or risk rates. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for upadacitinib: see also the generic vs brand label guide when reading Rinvoq SPL strings.
Read our methodology - how this data is sourced, computed, and verified.